The UK and US have secured a major commercial pact that will guarantee no tariffs on British drug products entering the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has agreed to increase expenditure on pharmaceuticals through the NHS. This move secures that import taxes on these key products will be held at zero for a period of 36 months.
This development follows previous threats to significantly raise import taxes on branded pharmaceutical imports, with potential rates mentioned up to 100%.
"This agreement with the UK bolsters the global environment for new treatments and introduces long-overdue balance to American-British pharmaceutical trade," a release declared.
Economic Impact
Drugs represent one of the the United Kingdom's biggest exports to the US, which is by far the primary buyer for leading companies like GSK and AstraZeneca.
Export figures show that in the year prior to the third quarter, the UK sold pharmaceutical products valued at £11.1bn to the US. This amount accounted for nearly one-fifth of British export trade in that timeframe.
"This guarantee safeguards work, increases capital expenditure and paves the way for the UK to establish itself as a worldwide center for life sciences," a minister remarked.
Key British Pledges
The agreement includes several key pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to increase overall public funding on medicines from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The sum manufacturers must return to the NHS to stay within budget will be restricted at fifteen percent. In the past, refunds were more than twenty percent.
Industry Background
The deal comes amid a ongoing dispute between the pharmaceutical industry and the ministers over drug pricing and NHS adoption.
These tensions were exacerbated by arguments that American consumers were charged a premium for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been paused or scrapped, while substantial funding commitments have been announced toward projects in the United States.
A senior figure stated that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had decreased as a share of its resources over the past decade.
